Potential of old-generation antibiotics to address current need for new antibiotics.
about
StreptomeDB: a resource for natural compounds isolated from Streptomyces speciesMolecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin ResistanceMolecular recognition and modification of the 30S ribosome by the aminoglycoside-resistance methyltransferase NpmA.Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia?Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.Bioactive Metabolites from the Deep Subseafloor Fungus Oidiodendron griseum UBOCC-A-114129.Aminoglycoside resistance rates, phenotypes, and mechanisms of Gram-negative bacteria from infected patients in upper Egypt.Cotrimoxazole and neonatal kernicterus: a review.Antagonism between bacteriostatic and bactericidal antibiotics is prevalentSelectively guanidinylated aminoglycosides as antibiotics.Stereocontrolled synthesis of syn-β-Hydroxy-α-amino acids by direct aldolization of pseudoephenamine glycinamide.Singly modified amikacin and tobramycin derivatives show increased rRNA A-site binding and higher potency against resistant bacteria.Follow-up of chronic coughers improves tuberculosis case finding: results from a community-based cohort study in southern Ethiopia30S Subunit-dependent activation of the Sorangium cellulosum So ce56 aminoglycoside resistance-conferring 16S rRNA methyltransferase Kmr.Characterization of the colistin (polymyxin E1 and E2) biosynthetic gene cluster.Detection of multi-drug resistant Escherichia coli in the urban waterways of Milwaukee, WINew insights in Staphylococcus pseudintermedius pathogenicity: antibiotic-resistant biofilm formation by a human wound-associated strain.Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy.Poly(trimethylene carbonate) as a carrier for rifampicin and vancomycin to target therapy-recalcitrant staphylococcal biofilms.Collective Resistance in Microbial Communities by Intracellular Antibiotic DeactivationA prospective evaluation of synergistic effect of sulbactam and tazobactam combination with meropenem or colistin against multidrug resistant Acinetobacter baumannii.Occurrence of aminoglycoside-modifying enzymes genes (aac(6')-I and ant(2″)-I) in clinical isolates of Pseudomonas aeruginosa from Southwest NigeriaSyntheses and Antibiotic Evaluation of 2-{[(2R,4R)-4-Carboxy-2-hydroxypyrrolidin-1-yl]carbonyl}benzene-1,5-dicarboxylic Acids and 2-Carbamoylbenzene-1,5-dicarboxylic Acid Analogues.Didactic CME and practice change: don't throw that baby out quite yet.Antibiotics resistance of Stenotrophomonas maltophilia strains isolated from various clinical specimens.Advances in MRSA drug discovery: where are we and where do we need to be?Quantitation of Polymyxin-Lipopolysaccharide Interactions Using an Image-Based Fluorescent Probe.Strategies for bypassing the membrane barrier in multidrug resistant Gram-negative bacteria.Pharmacological considerations for the proper clinical use of aminoglycosides.Silver nanoparticles: the powerful nanoweapon against multidrug-resistant bacteria.Combating multidrug-resistant bacteria: current strategies for the discovery of novel antibacterials.Prescribing patterns for upper respiratory tract infections: a prescription-review of primary care practice in Kedah, Malaysia, and the implications.A Perspective on the Trends and Challenges Facing Porphyrin-Based Anti-Microbial Materials.Multidrug efflux pumps and their role in antibiotic and antiseptic resistance: a pharmacodynamic perspective.In vitro activity of two old antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus.Frequency of colistin and fosfomycin resistance in carbapenem-resistant Enterobacteriaceae from a tertiary care hospital in Karachi.In Vitro and In Vivo Efficacy of an LpxC Inhibitor, CHIR-090, Alone or Combined with Colistin against Pseudomonas aeruginosa Biofilm.The innate growth bistability and fitness landscapes of antibiotic-resistant bacteria.[Multidrug-resistant bacteria in Germany. The impact of sources outside healthcare facilities].Synergistic antibiotic effect of looped antimicrobial peptide CLP-19 with bactericidal and bacteriostatic agents.
P2860
Q24595628-1F3866BD-9502-42D3-A761-5F2F4ABF02D3Q26853135-1C011DBF-E0A2-4CEA-A820-DBD67E700936Q27683164-916FE9F0-DE0D-457D-B953-3D492E0F4C75Q31004673-5E94B84F-FEA6-4E82-B748-765D5595E7EDQ33564290-F37F71E2-BB27-4A5B-9788-FDE74C21F219Q33612242-13DDFA0C-0B7E-4DE3-B43D-40FDCC0912B5Q33831880-CBDD08C7-812D-4BDB-BE98-FB86766EDA24Q33926897-9DF03D09-8100-4863-A7EA-F5714FBDBB9AQ34058001-C1781CAD-803A-487B-92EF-A35810EA2395Q34283886-45C8BB38-BE06-4930-AD76-56B604C87056Q34314946-12B3B941-D3C3-4BE2-BBE3-DC3656B2EC82Q34982853-02FBA4A5-8B32-425F-98E7-CBDA987E4EBCQ35125747-F6A1786E-EA80-44F1-8557-D6B716D0B49CQ35385472-9627ACC5-AC5A-4278-90C6-9513B0151A8DQ35546948-BE74D60C-49E4-42A6-A554-6A7D2D307735Q35550297-0B2EE10D-A160-45C4-AC8B-9C9DE500A6E5Q35637307-11209E50-7383-4F9C-B7E3-6995B271896AQ35657599-767053B5-4AF6-471F-A3A8-E0F7DEE9A3C7Q35923715-8AE62C58-7AA0-4A1F-A948-C8F85BBCE679Q36233864-19D99776-0D58-40BF-9C28-3BC08D590991Q36402290-322F1C3A-8DE3-47B0-81BC-204E833AF303Q36612635-CE74CD44-94CA-41A9-8D2B-384EA0A03678Q36626317-1C0566FF-95BD-4EDE-93A7-29594E474517Q36739827-053E27A6-EB9A-4EBE-8999-57201BBBD89DQ37025221-A9E7D05D-D5AA-4847-87E3-CCF8A86C5FB7Q37112508-BC692108-0783-411F-92A1-54FD537FE547Q37491825-E7118ACC-E139-4B61-A6C7-9E29FE229A0AQ37872942-6DE9C938-AB01-4EE1-BBB6-E3FCADC2DAA8Q37956403-9ABD1799-0460-4BF1-AC0B-AC5BD50D051CQ37983094-B46588E2-9F0F-4DD6-8ACA-BA832F368D6AQ38137920-F0D030E9-F831-47DC-8E91-8EED397CFBAEQ38584386-F20BFC20-C7CE-4724-B6E3-C2B27DEF3D20Q38858993-C6244212-2423-4F50-82FC-22CC8DF84062Q38986360-A74C789C-1879-4469-9660-D71C891CD869Q39833267-874BF279-3AB1-4D77-84B8-425A5E5E0EB0Q40090847-81CCD9B4-1DF3-4360-8141-3A2C9559A140Q40230660-8E996B05-B375-4F98-9E70-60AD334D36B3Q40768050-48E1F082-5ECF-4925-85BF-BC4AE58E7621Q40962124-4D156241-C74A-4871-812B-5B3F8F83B625Q41348363-1F2E33F1-4438-43CE-80DD-C0E1D681CA80
P2860
Potential of old-generation antibiotics to address current need for new antibiotics.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Potential of old-generation antibiotics to address current need for new antibiotics.
@ast
Potential of old-generation antibiotics to address current need for new antibiotics.
@en
Potential of old-generation antibiotics to address current need for new antibiotics.
@nl
type
label
Potential of old-generation antibiotics to address current need for new antibiotics.
@ast
Potential of old-generation antibiotics to address current need for new antibiotics.
@en
Potential of old-generation antibiotics to address current need for new antibiotics.
@nl
prefLabel
Potential of old-generation antibiotics to address current need for new antibiotics.
@ast
Potential of old-generation antibiotics to address current need for new antibiotics.
@en
Potential of old-generation antibiotics to address current need for new antibiotics.
@nl
P50
P356
P1476
Potential of old-generation antibiotics to address current need for new antibiotics.
@en
P304
P356
10.1586/14787210.6.5.593
P577
2008-10-01T00:00:00Z